Completed PHASE2 INTERVENTIONAL NCT00157534

A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection

Sponsor: BioWest Therapeutics Inc

Conditions Hepatitis C, Chronic

Interventions Celgosivir

Updated 4 times since 2017 Last updated: Sep 7, 2005 Started: Oct 31, 2004 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hepatitis C, Chronic, this trial is completed. The trial is conducted by BioWest Therapeutics Inc and has accumulated 4 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioWest Therapeutics Inc

Data source: BioWest Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.